Biotechnology

Complete Data from Connect Biopharma's Phase 1b Study of CBP-201 Demonstrate Rapid, Early and Continuous Improvement in Patient Quality of Life and Atopic Dermatitis (AD) Symptoms

Results from study in adult patients with moderate-to-severe AD presented at EADV Congress  SAN DIEGO and TAICANG, SUZHOU, China, Oct. 29, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune mo...

2020-10-29 19:00 1819

Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment

SUZHOU, China, Oct. 29, 2020 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharmaceutical, stock code 9939.HK) is delighted to announced that the clinical trial (ClinicalTrials.gov identifier: NCT04446429, registered by Dr. Andy Goren and Applied Biology) of its anti-androgen treatment Pro...

2020-10-29 18:24 3791

WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

* Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) * WuXi Biologics to undertake commercial-scale manufacturing to support U.S. market launch SHANGHAI and LAUSANNE, Switzerland, Oct. 2...

2020-10-29 17:00 2684

Deep Longevity and SquareOne Wellness Partner on Deep Biomarkers of Aging and Longevity

HONG KONG, Oct. 28, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; SEHK:0575.HK) today announced that Deep Longevity, Inc, a company recently acquired by the Group which  is a pioneer in deep biomarkers of agin...

2020-10-29 09:57 5262

Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia

SHANGHAI, Oct. 29, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, today announced that Australian regulatory authorities have approved it...

2020-10-29 09:35 1952

MolMed S.p.A Becomes AGC Biologics S.p.A Following the July Acquisition

AGC Biologics Now Provides End-to-End Cell and Gene Therapy CDMO Services SEATTLE, Oct. 28, 2020 /PRNewswire/ -- After its parent company AGC Inc. acquired 100% of the shares of MolMed S.p.A. onSeptember 30, 2020, AGC Biologics announced that MolMed's entity name has been changed to AGC Biologic...

2020-10-28 07:00 2247

TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm's history

- The Fund continues the proven "Project Focused Company" investment strategy for early-stage drug development candidates - In addition, the Fund continues to invest in late-stage clinical biopharmaceutical companies, medical device companies and diagnostic companies MUNICH and MONTREAL, Oct. 27...

2020-10-27 20:00 2546

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of MDM2-p53 Inhibitor APG-115 in Combination with Immunotherapy for the Treatment of Patients with Advanced Liposarcoma or other Advanced Solid Tumors in China

SUZHOU, China and ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eva...

2020-10-27 08:13 2375

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

* CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside ofGreater China * Agreement provides a pathway to bring CStone's sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) to global patient communities by partnering ...

2020-10-27 07:23 3502

Sai Life Sciences to significantly expand biology capabilities at its integrated R&D campus

HYDERABAD, India, Oct. 26, 2020 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations  (CRDMO), ...

2020-10-26 16:35 2186

RhoVac Participates in BIO Europe Digital

LUND, Sweden, Oct. 26, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that it is participating this week in the partnering event BIO Europe 2020 Digital. This week the digital version of the massive pharmaceutical partnering conference BIO Europe is held with participation from RhoVac...

2020-10-26 16:26 1496

TUV Rheinland Announces the Opening of its NABL Accredited Biomaterial and EMC Testing Laboratories

VISAKHAPATNAM, India, Oct. 23, 2020 /PRNewswire/ -- TUV Rheinland, a global leader in independent technical services announced the opening of its Biomaterial and EMC (Electro Magnetic Compatibility) Testing Laboratories located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam, Andhra Pradesh....

2020-10-23 09:15 2420

FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

PROVIDENCE, Rhode Island, Oct. 22, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year,$1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug ...

2020-10-22 21:00 2513

Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe Atopic Dermatitis (AD) at EADV Virtual Meeting

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 22, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune and inflammatory diseases, today announced it wil...

2020-10-22 19:30 1760

Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, Md., Oct. 21, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eva...

2020-10-21 17:37 2281

Cyclica to use Excelra's GOSTAR Database to develop AI & ML based Deep Learning Algorithm for Drug Target Identification

HYDERABAD, India and TORONTO, Oct. 21, 2020 /PRNewswire/ -- Excelra , a leading global Data & Analytics organization, today announced that it has licensed its Global Online Structure Activity Relationship Database (GOSTAR) to Cyclica Inc., a leading biotechnology company...

2020-10-21 10:00 4596

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end - ahead of schedule

HELSINKI, Finland, Oct. 21, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform "), an innovative nanoparticle medicine enabling company will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using Nanoform's proprietary CESS® technology. Dosing will ...

2020-10-21 02:14 4260

Key patent granted for Isla101 in Brazil

MELBOURNE, Australia, Oct. 20, 2020 /PRNewswire/ -- Isla Pharmaceuticals, a US-based company focused on rational repurposing of molecules for the treatment or prevention of viruses is pleased to announce that a key patent relating to the Company's lead program, Isla101 has been granted by the Bra...

2020-10-20 03:15 1993

analytica 2020 - free entry from the computer

Messe München and LUMITOS stage the largest virtual event of the year for the lab industry BERLIN, Oct. 16, 2020 /PRNewswire/ -- analytica, the world's leading trade fair for laboratory technology, analysis and biotechnology, will take place completely virtually in 2020. Visitors and exhibitors ...

2020-10-16 17:29 3656

Kazia Executes Agreement To Commence GBM Agile Pivotal Study

SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to commence Kazia's participat...

2020-10-16 07:30 12561
1 ... 153154155156157158159 ... 177